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levels of FFA-derived signaling lipids, 
such as LPA, within tumors. Finally, the 
antitumor effects of the MAGL-selective 
inhibitor used in this study suggest that 
MAGL is a promising therapeutic target 
for treating cancer. However, the critical 
role of MAGL in attenuating endocan-
nabinoid signaling in the brain could lead 
to behavioral side effects that are unique 
among cancer drugs (Long et al., 2009). 
It is clear that we are just beginning to 
understand the molecular contributions 
of alterations in lipid metabolism to can-
cer pathogenesis.
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The formation of the nervous system is 
a complex process that requires func-
tional microtubules during all stages of 
development. Events such as neurogen-
esis, neuronal migration, axon pathfind-
ing, and synapse formation are regulated 
by intrinsic and extrinsic pathways that 
ultimately impinge on the microtubule 
network, which carries out the structural 
changes that underlie each process. 
However, it is only recently that muta-
tions have been discovered in human 
genes encoding tubulin, the monomer 
that polymerizes into microtubules. 
Mutations in human genes such as 
TUB1A1 and TUBB2B, which encode 
α-tubulin and β-tubulin, respectively, or 
in genes that regulate microtubule func-
tion such as Lis1 and Doublecortin (Dcx) 
(des Portes et al., 1998; Gleeson et al., 
1998; Jaglin et al., 2009; Keays et al., 
2007; Poirier et al., 2007) give rise to dis-
orders of brain development. Such disor-
ders are characterized by lissencephaly 
(lack of brain folds) and polymicrogyria 
(excessive brain convolutions), which 
are caused principally by dysfunctional 
neuronal migration. In this issue of Cell, 
Tischfield et al. (2010) add to this grow-
ing literature with their report of new 
mutations in the human TUBB3 gene 
encoding neuronal βIII-tubulin. Using a 
multidisciplinary approach, they uncover 
TUBB3 mutations that produce diverse 
clinical phenotypes including ocular 
motility disorder (CFEOM3). Surprisingly, 
this is due primarily to disrupted axon 
guidance and not dysfunctional neuronal 
migration. This study elegantly examines 
the relationship among TUBB3 muta-
tions, their impact on microtubule func-
tion, and clinical symptoms.
Using a family-based approach, the 
authors identified eight heterozygous 
mutations in TUBB3. Clinically, the 
authors discovered that patients with the 
R262C mutation (the most commonly 
mutated residue) or the D417N mutation 
display hypoplasia of the ocular motor 
nerve and of several other nerve tracts, 
indicating defects in axon guidance and 
maintenance. Equally interesting is their 
observation that patients harboring dif-
ferent mutations in TUBB3 display a vari-
ety of clinical diagnoses. Although most 
patients suffer from CFEOM3, those 
with R262H, E410K, or D417H mutations 
also possess varying degrees of facial 
paralysis and progressive sensorimo-
tor polyneuropathy. This led the authors 
to speculate that a genotype-phenotype 
relationship exists, where a specific muta-
tion is associated with a particular set of 
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The microtubule network is crucial for the developing nervous system, and mutations in tubulin-
encoding genes disrupt neuronal migration. Tischfield et al. (2010) now report that mutations in 
the tubulin-encoding gene TUBB3 have a striking impact on microtubule dynamics in neurons, 
resulting in a diverse set of disease symptoms.
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clinical syndromes. Although 
these classifications would be 
an asset for genetic counsel-
ing, they are not absolute as 
there are varying degrees of 
a given clinical manifestation. 
Nonetheless, how do different 
clinical phenotypes arise from 
mutations within the same 
gene?
To answer this, the authors 
turned to mouse genetics 
and created a knock-in model 
of the most common muta-
tion, R262C. Analysis of mice 
with the homozygous R262C 
mutation in the Tubb3 gene 
revealed profound disruption 
of several axon tracts, includ-
ing oculomotor nerves, com-
missural axons, branching 
of cranial nerves, thinning of 
the anterior commissure, as 
well as stunted growth of the 
corpus callosum. These data 
strongly suggest that the pri-
mary defect is disrupted axon 
growth, which agrees well 
with the human imaging data 
and demonstrates the valid-
ity of using the Tubb3R262C/
R262C mouse as a model. Sur-
prisingly, the authors found 
that the neuronal layers in the cerebral 
cortex were normal with no evidence of 
structural defects. This suggests that the 
R262C mutation does not affect neuronal 
migration, which is also consistent with 
the lack of cortical layering abnormalities 
seen in patients with TUBB3 mutations.
The authors further characterized the 
mutant mice and speculated that the 
R262C mutation disrupts the biochemi-
cal properties of βIII-tubulin resulting in 
abnormal microtubule function. Indeed, 
the microtubules in neurons from these 
mutant mice show increased tyrosina-
tion, a posttranslational modification that 
increases microtubule stability. However, 
the microtubules also show decreased 
binding to Kif21a, a kinesin motor pro-
tein. This is very interesting given that 
humans with heterozygous mutations in 
Kif21a display isolated ocular motor dys-
function with signs of axon deficits in the 
cranial nerves, similar to patients with 
TUBB3 mutations (Yamada et al., 2003). 
Given that motor proteins such as the 
kinesins are important for transport of 
cargo along microtubules (De Vos et al., 
2008), decreased interaction between 
Kif21a and microtubules might lead to 
defective axonal transport of growth 
materials and signals necessary for axon 
outgrowth.
So how do the different mutations pro-
duce the different clinical phenotypes 
given that they are all located within βIII-
tubulin? To answer this, the authors per-
formed a series of in-depth biochemical 
and cell-imaging assays to determine 
the effects of the different mutations on 
microtubule function. First, a cell-free 
system was used to demonstrate that 
some of the mutations disrupted the abil-
ity of tubulin to form heterodimers, which 
is a prerequisite for tubulin polymerization 
into microtubules. Second, the authors 
used a yeast model system to test the 
effects of single TUBB3 mutations and 
found that all of the mutant yeast strains 
displayed some degree of resistance to 
pharmacologically induced microtubule 
destabilization. This supports 
previous experiments sug-
gesting that TUBB3 mutations 
increase microtubule stability. 
Finally, the authors turned to 
cell imaging using α-tubulin 
tagged with yellow fluores-
cent protein (YFP) or the YFP-
labeled kinesins Kip3p and 
Kip2p. These experiments 
revealed that some of the 
mutations caused microtu-
bule depolymerization rates 
to be less dynamic, resulting 
in increased microtubule sta-
bility. Interestingly, imaging 
of YFP-Kip3p and YFP-Kip2p 
revealed that many of the com-
mon TUBB3 mutations (E410, 
D417, and R262) reduced 
the localization of kinesins at 
microtubule tips. This sug-
gested that the mutations 
not only disrupt microtubule 
dynamics but also perturb the 
interaction of microtubules 
with proteins that use the 
microtubule system, similar to 
the observations in the mutant 
mice.
The Tischfield et al. study 
answers many questions 
stemming from the impact 
of TUBB3 mutations, but many more 
remain. First, why do mutations in 
TUBB3 produce axon growth defects, 
whereas mutations in TUBA1A and 
TUBB2B primarily produce neuronal 
migration disorders? Based on the dis-
ease phenotype, it is likely that the func-
tions of these genes differ during brain 
development; TUBB3 is possibly more 
important during axon guidance but dis-
pensable for neuronal migration. As loss 
of TUBB3 leads to increased microtu-
bule stability, this implies that neuronal 
migration may require increased micro-
tubule stability whereas axonal growth 
may require more dynamic microtubules 
in the growth cone. However, although 
the mutations produce different phe-
notypes, they all have the disruption of 
tubulin heterodimerization in common 
resulting in aberrant microtubule polym-
erization (Figure 1). A second question 
is whether TUBB3 mutations disrupt the 
interaction of microtubules with tubulin-
interacting proteins. The authors’ data 
figure 1. Microtubules and Brain Development
Human genetic studies have revealed that mutations in genes encoding tu-
bulin, the monomer that polymerizes into microtubules, lead to a variety of 
defects during brain development associated with abnormal neuronal migra-
tion and axon guidance. Mutations in the TUBA1A gene encoding α-tubulin 
lead to type I lissencephaly (smooth brain), whereas mutations in the TUBB2B 
gene encoding β-tubulin lead to polymicrogyria (convoluted brain) character-
ized by prematurely arrested neurons in the deeper cortical layers. Mutations 
in TUBB3, which encodes βIII-tubulin, produce a different clinical syndrome 
(ocular motility disorder) primarily due to disrupted axon guidance during 
brain development. Furthermore, TUBB3 mutations lead to impaired interac-
tions of kinesin motor proteins with microtubules and increased microtubule 
stability, which contributes to the axon guidance defects. Although the muta-
tions in the tubulin-encoding genes result in different disorders, all of them 
impair the formation of tubulin heterodimers. This would eventually result in 
suboptimal microtubule dynamics during various developmental events. Pa-
tients with TUBA1A and TUBB2B mutations (gray lines) also display evidence 
of disrupted axon tract formation, but it is unclear whether this is a secondary 
deficit due to the inhibition of neuronal migration.
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suggest that TUBB3 mutations inhibit 
the interaction of microtubules with kine-
sin motor proteins. However, as tubulin 
subunits must interact with molecular 
chaperones to fold appropriately before 
microtubule polymerization (Lewis et al., 
1997), it is possible that TUBB3 muta-
tions also perturb the interaction of 
tubulin with chaperones or other tubulin-
modifying proteins. The answer to this 
question may also provide insight into 
why different TUBB3 mutations give rise 
to distinct clinical conditions. For exam-
ple, it is possible that different genetic 
mutations may hinder the interaction of 
tubulin with individual tubulin-interacting 
proteins (including chaperones), which 
are expressed and utilized at different 
neurodevelopmental time points, leading 
to different clinical outcomes. Although 
the current study warrants further inves-
tigation, TUBB3 mutations, together with 
the recent discovery of human TUBB2B 
and TUBA1A mutations, clearly demon-
strate that microtubule dynamics play a 
key role in brain development.
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